Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report

Mult Scler Relat Disord. 2020 Sep:44:102323. doi: 10.1016/j.msard.2020.102323. Epub 2020 Jun 22.

Abstract

The emergency represented by the COVID-19 pandemic represents a new challenge for clinicians who deal with autoimmune diseases because of patients undergoing immunosuppressive therapy. Few cases of Multiple Sclerosis (MS) patients receiving ocrelizumab who contracted COVID-19 with a benign course have recently been published. We present the case of a MS patient with mild COVID-19 who developed SARS-CoV-2 specific IgA without IgG ten weeks after infection. Patients on B-cell depleting drugs have a reduced antibody immune response to viral neoantigens. A relative sparing of mucosal-associated lymphoid tissues (MALT) could be responsible for IgA response in our patient.

Keywords: COVID-19; IgA; IgG; Ocrelizumab; Serology.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • COVID-19 / complications
  • COVID-19 / diagnosis*
  • COVID-19 / immunology*
  • COVID-19 Serological Testing*
  • Female
  • Humans
  • Immunoglobulin A / analysis
  • Immunoglobulin A / immunology
  • Immunoglobulin G / analysis
  • Immunoglobulin G / immunology
  • Immunologic Factors / therapeutic use*
  • Middle Aged
  • Multiple Sclerosis / complications
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / immunology*

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin A
  • Immunoglobulin G
  • Immunologic Factors
  • ocrelizumab